Clinical Trials Logo

Filter by:
NCT ID: NCT02769559 Completed - Quality of Life Clinical Trials

Reduction Mammaplasty and Improved Quality of Life

MammaRed
Start date: January 2000
Phase: N/A
Study type: Observational

The data gathered here will be used to evaluate the efficacy and safety of the mammary reduction in patients with macromastia.

NCT ID: NCT02761252 Completed - Asthma Clinical Trials

Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma

SKY
Start date: April 13, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare concomitant administration of Montelukast and Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma

NCT ID: NCT02755649 Completed - Atopic Dermatitis Clinical Trials

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Start date: January 31, 2016
Phase: Phase 3
Study type: Interventional

The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral Cyclosporine A (CSA), or when this treatment is currently not medically advisable. The secondary objective is to assess the safety and tolerability of 2 dose regimens of dupilumab compared to placebo, administered with concomitant TCS, in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral CSA, or when this treatment is currently not medically advisable.

NCT ID: NCT02753946 Completed - Clinical trials for Acute Pyelonephritis

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

ZEUS
Start date: April 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin) as non-inferior to piperacillin/tazobactam in overall success (clinical cure and microbiologic eradication) for the treatment of hospitalized patients with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP).

NCT ID: NCT02753712 Completed - Asthma Clinical Trials

A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

Start date: June 15, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).

NCT ID: NCT02752776 Completed - Plaque Psoriasis Clinical Trials

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

PROSE
Start date: March 17, 2016
Phase: Phase 4
Study type: Interventional

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

NCT ID: NCT02751931 Completed - Clinical trials for Neurogenic Detrusor Overactivity

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Crocodile
Start date: June 17, 2016
Phase: Phase 3
Study type: Interventional

The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.

NCT ID: NCT02745080 Completed - Psoriatic Arthritis Clinical Trials

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

EXCEED 1
Start date: April 3, 2017
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).

NCT ID: NCT02742311 Completed - Back Pain Clinical Trials

EuroPainClinics® Study V (Prospective Observational Study)

EPCSV
Start date: December 31, 2021
Phase: N/A
Study type: Interventional

In this prospective observational trial the effect of the Endoscopic discectomy microinvasive therapy should be examined in (approximately 500) adult patients with low back pain.

NCT ID: NCT02738151 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

BRIGHT
Start date: May 19, 2016
Phase: Phase 4
Study type: Interventional

Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24. Secondary Objectives: Change From Baseline in HbA1c to Week 12 To assess the effects of the insulin Toujeo® in comparison with insulin Tresiba® at week 12 and week 24 on: - Change in Fasting plasma glucose (FPG); - Change in Fasting self-monitored plasma glucose (SMPG) and 4-point SMPG and 8-point SMPG profile; - Percentage of participants reaching HbA1c targets <7% or ≤6.5%; - Percentage of participants reaching HbA1c targets <7% or ≤6.5% without severe and/or confirmed hypoglycemia - Frequency of occurrence and diurnal distribution of hypoglycemia by American Diabetes Association (ADA) category of hypoglycemia. To assess the safety in each treatment group. To assess the treatment effects in each treatment group on Patient Reported Outcomes (PRO). Percentage of participants requiring rescue therapy.